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hyperglycemic status caused by either the loss of insulin production due to the destruction of beta 48 pancreatic cells, decreased insulin sensitivity, or both [1, 2] . In 2014, the global prevalence of 8.3% 49 has been estimated and by the end of 2030 this value is expected to rise up to 55% [3] , resulting in 50 obvious devastating consequences for healthcare expenditure worldwide. All the antidiabetic drugs 51 currently available, although effective in reducing the risk of acute complications, such as 52 hypoglycemia and hyperglycemia [4] , are not effective in reversing the progression of this chronic 53 and degenerative disorder. Indeed, diabetic patients are still at a high risk to develop longstanding 54 complications including cardiovascular disease, such as coronary artery disease, and microvascular 55 diseases, including neuropathy, retinopathy and nephropathy. Therefore, a better understanding of 56 the underlying pathophysiology should contribute to new effective therapeutic approaches. Among 57 the different mediators proposed to contribute to the pathophysiology of diabetes, histamine 58 involvement has always been controversial and considered almost marginal. However, several lines 59 of evidence support the contribution of histamine to the diabetic milieu resulting from the persistent 60 hyperglycemia. For instance, the advanced glycation end-products (AGEs) have been demonstrated 61 to activate mast cells whose degranulation may contribute to a vicious cycle, ultimately resulting in 62 a low-grade inflammation typical of chronic diseases such as diabetes [5] . Therefore, this review 63 aims to revisit the concept of histamine in the pathophysiology of diabetes and, in particular, its 64
complications. 65

Histamine and glycaemia 66
Histamine is involved in a wide variety of pathophysiological events mostly related to the 67 inflammatory response through four receptors, namely H 1-4 Rs. The first studies of histamine and 68 diabetes date back to the 1950s. Since that time the involvement of histamine in diabetes was 69 literature can be specifically explained by the observation that the H 3 R receptor is expressed both as 221 an autoreceptor and heteroreceptor which inhibits the release of histamine [97] and other 222 neurotransmitters, respectively, including acetylcholine, noradrenaline, dopamine and serotonin 223 [98] [99] [100] [101] [102] . 224 Notably, histamine has also been shown to play a role in autonomic neuropathy. Indeed, the 225 deranged autonomic function of the airways in diabetic patients with autonomic neuropathy has 226 been demonstrated to elicit an exaggerated response to histamine-induced bronchoconstriction 227 [103] . A direct stimulation of bronchial smooth muscle contraction combined with vagal-mediated 228 reflexes after stimulation of rapidly adapting irritant receptors and C-fibers has been argued to be 229 the mechanism underling the histamine-induce bronchoconstriction, while bronchomotor tone is 230 mainly controlled by the parasympathetic nervous system. Therefore, the exaggerated response to 231 histamine in diabetic patients could be due to the widespread autonomic damage to the respiratory 232 parasympathetic and sympathetic pathways (including non-adrenergic non-cholinergic pathways 233 influencing airway tone) and/or denervation hypersensitivity [104] [105] [106] [107] [108] [109] [110] [111] . However, despite the above 234 observations the role of histamine in autonomic neuropathy is still far from clear. 235
Diabetic retinopathy 236
Diabetic retinopathy is still one of the major worldwide cause of blindness. Its development can be 237 divided into non-proliferative, with microaneurysms, hard exudates, haemorrhages, and venous 238 abnormalities and proliferative, with neovascularization, pre-retinal or vitreous haemorrhages, and 239 fibrovascular proliferation [112, 113] . Development of glaucoma, retinal detachment, and vision 240 loss may also happen at this stage [114] . 241
A possible role for histamine in this context was postulated when diabetic retinopathy was mainly 242 considered a microvascular complication of endothelial dysfunction with capillary basement 243 membrane (BM) thickening, pericyte and endothelial cell loss, blood-retinal barrier (BRB) 244 breakdown and leakage, acellular capillaries, and neovascularization [115, 116] . Indeed, most of 245 11 these vascular effects are consistent with the vasoactive properties of histamine. Antihistamines, 246 such as diphenhydramine (PubChem CID 3100), astemizole (PubChem CID 2247) and ranitidine 247 (PubChem CID 3001055), have been shown to reduce the leakage of retinal vessels in diabetic rats 248 and humans [117, 118] , but also to attenuate blood-brain barrier permeability and to ameliorate 249 cerebral blood flow disturbances [119] . 250
In particular, it was reported that histamine specifically affects the zonula occludent (ZO)-1 251 expression in cultured retinal microvascular endothelial cells [120] . Interestingly, the same authors 252 described a similar inhibitory effect on ZO-1 expression for both high glucose (20mM) and low 253 insulin (10 -12 M) culturing condition [121] . These data provide a mechanistic interpretation of the 254 ability of histamine to induce a BRB dysfunction in both experimental diabetes and diabetic 255 patients [118, 122, 123] , suggesting that the increased histaminergic tone consequent to the diabetic 256 milieu could directly account for the BRB breakdown and leakage vascular, for many years 257 considered pivotal in the pathogenesis of diabetic retinopathy. These effects can be considered at 258 least qualitatively equivalent to those observed for the vascular endothelial growth factor (VEGF) 259 on permeability leakage [124] . 260
The possible involvement of histamine in diabetic retinopathy is still plausible, although not deeply 261 investigated, when, according to the neurodegenerative nature of this disease, the other components 262 of the retina, such as neurons and glial cells are taken into account. It is currently acknowledged 263 that cellular, molecular, and functional changes are evidenced in all the retina cellular 264 compartments [115, 116, [125] [126] [127] at an early stage of diabetic retinopathy. Intriguingly, an 265 increase in histamine synthesis was observed within the retinas of diabetic rats [117, 128] . This was 266 due to an over-expression of the HDC enzyme in both the retinal neurons and glia [129] . As 267 mentioned above for plasma, aorta and pancreas, an insulin-histamine loop does exist also within 268 the retina. The histamine overproduction induced by diabetes was decreased by both the HDC 269 inhibitor or insulin administration in experimental diabetes [128] . 270 Therefore, collectively the data in the literature suggest that histamine could at least participate in 271 the neural cell contribution to the diabetes-induced vascular leakage. 272
Diabetic nephropathy 273
Diabetic nephropathy is one of the most important causes of chronic kidney disease (CKD), and 274 therefore of end-stage renal disease (ESRD) in Western nations. It has been estimated that the risk 275 of developing CKD is increased by a factor of 12-fold in type 1 diabetes and 6-fold in type 2 276 diabetes, compared with non-diabetic individuals [130] . About one-third of diabetic patients begin 277 to show persistently high urinary albumin excretion, thence being at high risk to develop in primis 278 diabetic ESRD, but also cardiovascular diseases and premature mortality, even without progression 279 to ESRD [131] . shows growing independent lines of evidence for a bidirectional connection between histamine and 327 diabetes (Table I) . 328 Table I , not all the diabetic complications have been provided with the same level of 340 compelling evidence. Many blind spots remain regarding the role of histamine in macrovascular 341 complications where the effect of the amine seems to be mostly related to its general vasoactive 342
properties rather than to a specific function in diabetes. The discrepancies often observed in the 343 literature can be mostly ascribed to the different models adopted as well as to the doses, the 344 administration route and the actual selectivity of the compound used, which could differentially 345 affect the central and peripheral histaminergic system. More notably, the majority of the evidence 346 for histamine involvement in the different diabetes complications arises from studies not directly 347 aimed to assess its role in diabetic disease. This is in particular the case for diabetic peripheral 348 neuropathy where the studies were designed to assess a general role in nociception and/or 349 
